Sanofi’s profits to dip as its dengue vaccine faces dire criticism
Date: 2017-11-30   Author: Dhananjay Punekar  Category: #news

In a turning tide of the events, the use of Sanofi’s new vaccine for dengue has been severely restricted, owing to the evidence that it can lead to further deterioration in patients who have not been infected with the ailment before. The chief officials of Sanofi are expected to make suggestions to the national regulatory authorities in France that the vaccination should not be prescribed for patients who have no history of being infected by dengue.

As per medical experts, results obtained from the clinical tests performed on the patients a few years earlier depicted that the Dengvaxia vaccine offered a constant shield against dengue to those patients who were earlier affected due to the ailment. However, later on, it was found that people who were not afflicted by the virus suffered much more post the vaccination.

Initially, the firm had predicted bright growth prospects for its dengue vaccine, projecting that it would accrue a revenue of nearly EUR 1 billion per year from its sales. But, as per the estimates its sales in 2016 were assessed at EUR 55 million, much below expectations. A reliable research group has forecast that the yearly sales of Dengvaxia vaccine will reach EUR 360 million by 2022.  Sources have claimed that dengue infects millions across the globe and nearly 20,000 persons lose their lives due to the disease each year.

Though Sanofi’s Dengvaxia is the first approved vaccine of its kind, research has already depicted the limitations of vaccination through mixed results obtained from the data of clinical tests conducted on four dissimilar kinds of virus. It is anticipated that the business rivals of the firm such as Takeda Pharmaceutical are also developing an improved version of a vaccine against dengue, which can significantly impact Sanofi’s market position over the coming years.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Australia to ban Huawei’s participation in 5G mobile telecom rollout
Author: Dhananjay Punekar

In a major blow to China-Australia relations, Australia is planning to exclude Huawei from the list of participants invited for the 5G mobile telecom rollout in the country. Reportedly, the country fears that the Chine...


Siemens pioneers facility to use ammonia for renewable energy storage
Author: Dhananjay Punekar

Siemens AG, a German firm headquartered in Munich, has inaugurated a £1.5 million pilot venture in Oxfordshire, with an aim to promoting the use of ammonia as a new kind of energy storage. Reportedly, the firm wa...


Shell offers engineering contract to Subsea 7 for Penguins Project
Author: Dhananjay Punekar

Royal Dutch Shell PLC, a renowned oil & gas firm, has offered Subsea 7 S.A., a UK based engineering, construction, and services firm, a contract for the redevelopment of its Penguins oil & gas field located in ...